Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Chronic Lymphocytic Leukemia
- Registration Number
- NCT00086203
- Lead Sponsor
- Point Therapeutics
- Brief Summary
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
- Detailed Description
Completion date provided represents the completion date of the grant per OOPD records
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (19)
University of Arkansas for Medical Science
🇺🇸Little Rock, Arkansas, United States
Ocala Oncology Center
🇺🇸Ocala, Florida, United States
Gulfcoast Oncology Associates
🇺🇸St. Petersburg, Florida, United States
Indiana Oncology/Hematology Consultants
🇺🇸Indianapolis, Indiana, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Hematology/Oncology Centers of the Northern Rockies
🇺🇸Billings, Montana, United States
Nevada Cancer Institute
🇺🇸Las Vegas, Nevada, United States
Queens Medical Associates, PC
🇺🇸Fresh Meadows, New York, United States
Long Island Jewish Medical Center
🇺🇸New Hyde Park, New York, United States
NYU Medical Center
🇺🇸New York, New York, United States
Scroll for more (9 remaining)University of Arkansas for Medical Science🇺🇸Little Rock, Arkansas, United States